AstraZeneca is bracing up its battle to receive reimbursement approval for its Koselugo (selumetinib, AZ) within the year. The company’s new neurofibromatosis drug was unable to pass review by the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee last year.

AstraZeneca submitted its 3rd supplementary material and RSA proposal recently. Whether the agenda will be reviewed at HIRA’s DREC meeting and determined adequate for reimbursement is receiving attention.

According to industry sources on the 16th, AZ withdrew its previous drug listing and reimbursement price application for Koselugo in January and submitted a new a